ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM

AZD1775 is an oral small molecular inhibitor of the G2/M checkpoint regulator Wee1. The Adult Brain Tumor Consortium 1202 trial (NCT01849146) is a phase I, open label, multicenter dose-finding study of AZD1775 in combination with standard RT and TMZ followed by an IDD study for patients undergoing s...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Alexander, Brian, Supko, Jeffrey, Agar, Nathalie, Ahluwalia, Manmeet, Desai, Arati, Dietrich, Jorg, Kaley, Thomas, Peereboom, David, Takebe, Naoko, Desideri, Serena, Fisher, Joy, Sims, Megan, Ye, Xiaobu, Ligon, Keith, Nabors, L Burt, Grossman, Stuart, Wen, Patrick
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Abstracts
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216169/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.048
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki